Profile data is unavailable for this security.
About the company
Baudax Bio, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing products for hospital and related acute care settings. The Company's lead product candidate is ANJESO injection. ANJESO is a cyclooxygenase-2 (COX-2), a preferential, non-steroidal anti-inflammatory for the management of moderate to severe pain, which could be administered alone or in combination with other non-NSAID analgesics. Its pipeline of other pharmaceutical products includes two neuromuscular blocking agents (NMBs) and a chemical reversal agent, which are used as muscle paralyzing agents to facilitate intubation and surgery. Its product pipeline includes NMBAs, which are used as muscle paralyzing agents to facilitate intubation and surgery. It is developing intermediate-acting NMBA, BX-1000, an ultrashort-acting NMBA, BX-2000, and a reversal agent specific to its NMBAs. It is also focused on the discovery and development of Treg-based cell therapies for autoimmune diseases.
- Revenue in USD (TTM)310.00k
- Net income in USD-25.83m
- Incorporated2019
- Employees9.00
- LocationBaudax Bio Inc490 Lapp RoadMALVERN 19355United StatesUSA
- Phone+1 (484) 395-2470
- Fax+1 (484) 395-2471
- Websitehttps://www.baudaxbio.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Adhera Therapeutics Inc | 0.00 | -4.61m | 57.77k | 1.00 | -- | -- | -- | -- | -1.12 | -1.12 | 0.00 | -5.10 | 0.00 | -- | -- | -- | -2,989.56 | -460.83 | -- | -- | -- | -- | -- | -12,489.02 | -- | -0.509 | -- | -- | -- | -- | 67.47 | -- | -- | -- |
| Baudax Bio Inc | 310.00k | -25.83m | 113.34k | 9.00 | -- | -- | -- | 0.3656 | -17.25 | -9.17 | 0.0778 | -0.0985 | 0.0163 | -- | -- | 34,444.45 | -135.61 | -112.14 | -- | -192.87 | -1,445.81 | -- | -8,331.61 | -9,179.73 | -- | -- | 1.30 | -- | 17.50 | -- | -164.95 | -- | -56.52 | -- |
| Ampio Pharmaceuticals Inc | 0.00 | -8.63m | 113.54k | 6.00 | -- | 0.0248 | -- | -- | -11.10 | -11.10 | 0.00 | 4.03 | 0.00 | -- | -- | 0.00 | -89.34 | -72.16 | -109.57 | -84.33 | -- | -- | -- | -- | 2.32 | -- | 0.00 | -- | -- | -- | 47.16 | -- | -- | -- |
| Propanc Biopharma Inc | 0.00 | -2.46m | 159.58k | 1.00 | -- | -- | -- | -- | -0.3033 | -0.3033 | 0.00 | -0.0337 | 0.00 | -- | -- | -- | -2,440.90 | -4,945.87 | -- | -- | -- | -- | -- | -- | -- | -1.70 | -- | -- | -- | -- | -17.63 | -- | -- | -- |
| ContraFect Corp | 0.00 | -24.14m | 161.64k | 23.00 | -- | -- | -- | -- | -19.25 | -19.25 | 0.00 | -0.538 | 0.00 | -- | -- | 0.00 | -150.12 | -74.17 | -- | -94.04 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -221.24 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Black Horse Capital Management LLCas of 07 Sep 2023 | 500.00k | 1.15% |
| Sittner & Nelson LLCas of 31 Mar 2024 | 1.00 | 0.00% |
| Woodbury Financial Services, Inc.as of 31 Dec 2023 | 0.00 | 0.00% |
| Avior Wealth Management LLCas of 31 Mar 2024 | 0.00 | 0.00% |
